Novartis AG (NVS)
NYSE (ADR) / SIX · Basel, Switzerland · Founded 1996 · CEO Vasant Narasimhan
Valuation summary
$127.42 fair value versus $151.22 in the market, a difference of -15.7%. Rated Reduce.
| Fair value per share | $127.42 |
| Current share price | $151.22 |
| Upside / downside | -15.7% |
| Bear case | $83.74 |
| Bull case | $190.41 |
| Discount rate (WACC) | 8.2% |
| Terminal growth | 2.20% |
| Market capitalisation | $244B |
| EV / Sales | 4.2x |
About Novartis AG
Created in 1996 from the merger of Ciba-Geigy and Sandoz, both Basel chemical and pharmaceutical houses with roots in the 1750s. Vasant Narasimhan is CEO. After spinning off the Sandoz generics business in 2023 and the Alcon eye care business in 2019, Novartis is a focused innovative medicines company. Key products include Entresto for heart failure, Cosentyx in immunology, Kisqali in breast cancer, Kesimpta for multiple sclerosis, and the radioligand therapy Pluvicto — a genuinely differentiated cancer treatment that delivers radiation directly to tumour cells.
Investment case
- Radioligand therapy is a differentiated platform with manufacturing complexity that acts as a barrier to entry.
- Post-spin-off, the portfolio is cleaner and margins have improved materially.
- Swiss domicile and strong cash generation support a reliable, growing dividend.
Key risks
- Entresto has begun losing exclusivity, removing a large revenue contributor.
- Growth is mid single digits, which limits the multiple the market will pay.
- Two Phase 3 failures in September 2026, pelacarsen in cardiovascular outcomes and del-desiran from the $12B Avidity acquisition, show how much the pipeline depends on a few high-value assets.
Recent developments
- 2026-10-28 · Q3 net sales up 4% to $14.5bn and core EPS up 9% to $2.46; full-year core operating income guidance raised source
- 2026-09-11 · Major shareholder Artisan Partners said the board 'failed to properly scrutinize deals' after trial setbacks undermined the $12B Avidity acquisition. source
- 2026-09-08 · Phase 3 HARBOR of del-desiran, from the Avidity deal, missed its primary endpoint in myotonic dystrophy; NVS ADR closed down 14% at $137.63. source
- 2026-09-07 · Pelacarsen lowered Lp(a) but failed to reduce cardiovascular events in the 8,000-patient Phase 3 Lp(a)HORIZON trial. source
Revenue by segment
| Oncology & Haematology | 40% |
| Immunology & Neuroscience | 32% |
| Cardio-Renal-Metabolic | 20% |
| Other | 8% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $62.7B | $13.4B |
| Year 2 | $64.1B | $13.5B |
| Year 3 | $65.6B | $13.6B |
| Year 4 | $67.2B | $13.7B |
| Year 5 | $68.7B | $13.8B |
What the street says
Seen as a well-run European pharma, but two Phase 3 failures in September 2026 cut the ADR 14% in a day and drew criticism from a major shareholder over the board's scrutiny of acquisitions. The debate is whether the pipeline can sustain growth once Entresto erosion completes.
Comparable companies: NVO · GILD · TMO · AZN · JNJ · MRK · PFE · DHR
Open the interactive model, price chart and sensitivity grid →